BioStock: CLS continues toward the goal of becoming cash flow positive by 2026

2024 was a pivotal year for CLS, as the company adopted a sharper strategy and launched the full market rollout of its laser ablation system for neurosurgery. Revenue more than doubled, and the operating result improved. The company is now focusing on strengthening sales and continuing toward its goal of becoming cash flow positive within two years.

Read the full article at biostock.se:

https://www.biostock.se/en/2025/02/cls-continues-toward-the-goal-of-becoming-cash-flow-positive-by-2026/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se